Education
About Us
Working with TipRanks
Follow Us
ADC Therapeutics Ltd (ADCT)
NYSE:ADCT
ADCT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.05 - $5.17
Previous CloseN/A
Volume185.04K
Average Volume (3M)360.96K
Market Cap
$134.88M
Enterprise Value$81.87M
Total Cash (Recent Filing)-$262.75M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.82
Next Earnings
May 12, 2025EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.66
Shares Outstanding99,178,280
10 Day Avg. Volume278,142
30 Day Avg. Volume360,959
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.89
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.29
Enterprise Value/Ebitda-0.73
Forecast
1Y Price Target
$7.75Price Target Upside469.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
ADC Therapeutics News
PremiumCompany Announcements
ADC Therapeutics Earnings Call: Optimism Amid Challenges
PremiumCompany Announcements
ADC Therapeutics Reports Strong 2024 Financials and Trial Progress
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsTreatment with ZYNLONTA + glofitamab generated a 94% overall response rate (ORR) with a 72% complete response (CR) rate.
Financial PerformanceADC Therapeutics recorded a net loss of $0.29 per share—narrower than previously estimated net loss of $0.41 per share.
Future Operational CapacityThe company's balance sheet resources should provide an operational runway through multiple data catalysts.
Bears Say
Market UptakeSlower than anticipated market uptake for ADCT-402 is identified as a risk.
Regulatory Approval RisksRisks include the inability to obtain timely approval for ADCT-402 in diffuse large B-cell lymphoma.
Sales PerformanceZYNLONTA's 4Q24 sales fall relative to 3Q24.
---
Ownership Overview
33.41% Insiders
1.84% Mutual Funds
0.14% Other Institutional Investors
60.42% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ADCT FAQ
What was ADC Therapeutics Ltd’s price range in the past 12 months?
ADC Therapeutics Ltd lowest stock price was $1.05 and its highest was $5.17 in the past 12 months.
What is ADC Therapeutics Ltd’s market cap?
ADC Therapeutics Ltd’s market cap is $134.88M.
When is ADC Therapeutics Ltd’s upcoming earnings report date?
ADC Therapeutics Ltd’s upcoming earnings report date is May 12, 2025 which is in 16 days.
How were ADC Therapeutics Ltd’s earnings last quarter?
ADC Therapeutics Ltd released its earnings results on Mar 27, 2025. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.412 by $0.122.
Is ADC Therapeutics Ltd overvalued?
According to Wall Street analysts ADC Therapeutics Ltd’s price is currently Undervalued.
Does ADC Therapeutics Ltd pay dividends?
ADC Therapeutics Ltd does not currently pay dividends.
What is ADC Therapeutics Ltd’s EPS estimate?
ADC Therapeutics Ltd’s EPS estimate is -0.4.
How many shares outstanding does ADC Therapeutics Ltd have?
ADC Therapeutics Ltd has 99,178,280 shares outstanding.
What happened to ADC Therapeutics Ltd’s price movement after its last earnings report?
ADC Therapeutics Ltd reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.412. Following the earnings report the stock price went down -3.797%.
Which hedge fund is a major shareholder of ADC Therapeutics Ltd?
Currently, no hedge funds are holding shares in ADCT
---
ADC Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.75 (469.85% Upside)
$7.75 (469.85% Upside)
Blogger Sentiment
Bullish
ADCT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $609.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 11.4%
Last 30 Days ▼ 11.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.54%
12-Months-Change
Fundamentals
Return on Equity
123.38%
Trailing 12-Months
Asset Growth
-9.25%
Trailing 12-Months
Company Description
ADC Therapeutics Ltd
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
---
ADCT Company Deck
---
ADCT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements in clinical trials, financial strengthening, and potential revenue growth for ZYNLONTA. However, it also acknowledged challenges such as competition in the DLBCL market and flat revenue growth. Despite these challenges, the company remains optimistic about its future prospects.Read More>---
ADCT Stock 12 Month Forecast
Average Price Target
$7.75
▲(469.85% Upside)
Technical Analysis
Larimar Therapeutics
―
TuHURA Biosciences
―
RAPT Therapeutics
―
Kalaris Therapeutics
―
Silence Therapeutics
―
Best Analysts Covering ADCT
1 Year
1 Year Success Rate
7/22 ratings generated profit
1 Year Average Return
+0.64%
reiterated a buy rating 24 days ago
Copying Gregory Renza's trades and holding each position for 1 Year would result in 31.82% of your transactions generating a profit, with an average return of +0.64% per trade.
---